Muscle loss on GLP-1 medicines: how much, and what helps

Lean mass is not the same as muscle

The body scans in these trials use a method called DXA, a low-dose X-ray that sorts the body into fat, bone and everything else. Everything else is called lean mass. It includes skeletal muscle, and it also includes organs, skin and water.

So a drop in lean mass is a warning light, and it does not say exactly how much muscle was lost. Keep that in mind for every number on this page. The same scans also show how much fat was lost, which is where most of the weight comes off.

How much of the weight lost is lean mass?

Three sources give a sense of the range. None of them is a promise about your own result.

Each source reports its own measure, so the rows are not directly comparable. Percentages are either a share of the weight lost or a percent change, as the source states.

What the numbers suggest

The share is similar to what diet-and-exercise programs show, so the medicines do not appear unusually hard on muscle compared with losing the same weight another way. Because the medicines cause larger weight loss, the amount of lean mass lost is larger too. In the tirzepatide scan study, lean mass fell 10.9% against 2.6% on placebo.

BELIEVE adds a caution. Its participants were counseled to eat at least 1.2 g of protein per kg a day and to stay active, and the semaglutide groups still lost lean mass. Advice to eat protein and move is sensible, and it is not a guarantee.

Does losing lean mass matter?

That is the open question. A 2025 review said it remains unclear whether these lean-mass changes lead to weaker muscles or more frailty, because studies have been small, scans differ from study to study and few measured strength or daily function. A 2026 review said the loss is generally in proportion to the weight lost and should not be read as the medicine damaging muscle. It named older adults and people with little muscle reserve as the groups to think about most.

Bone is the other thing researchers watch. In BELIEVE, hip bone density, an exploratory measure, fell 2.1% in the semaglutide 2.4 mg group against 0.8% on placebo at 48 weeks. The authors suggested that less mechanical loading with weight loss may play a part.

What has evidence for protecting muscle

The Atlas did not find a finished randomized trial that tested a protein amount or a lifting program in people taking semaglutide or tirzepatide. The LEAN-PREP trial plans to, with 232 adults over six months and thigh muscle size on MRI as its main measure. Only its plan has been published. The protein page and the exercise page go deeper on each.

Medicines built to protect muscle: what is real and what is hype

Two antibody medicines have been tested alongside GLP-1 medicines. Both are given by infusion in the trials. Bimagrumab is not approved for any use that the Atlas found. Apitegromab is approved only for a different condition, spinal muscular atrophy, as of September 2026, and not for protecting muscle during weight loss.

Neither result has been confirmed in a larger trial.

Where the hype comes in

Headlines about "55% more muscle" are a misreading. The apitegromab result is about 1.9 kg less lean mass lost over 24 weeks on a scan, not 55% more muscle gained. Bimagrumab did add a little lean mass when given alone, but that group lost much less weight than semaglutide did.

What is next is still unsettled. Lilly has a second trial pairing bimagrumab with tirzepatide, with 252 adults and injections under the skin. It has finished enrolling, and the Atlas did not find results. A Massachusetts General Hospital trial of the same pairing is recruiting. A Lilly trial in people with type 2 diabetes was withdrawn with no one enrolled, and the Atlas did not find a public reason. None of this is available outside a trial.

Who needs to be careful

• Protein: the 1.2 to 1.6 g per kg range in the 2026 review was proposed for adults without chronic kidney disease. With kidney disease, ask your kidney clinician before changing protein.
• Exercise: anyone with heart disease, chest pain or breathlessness, joint problems, or a long gap since last exercising should check with a clinician first.
• Very low food intake: eating much less overall makes it harder to get enough of any nutrient, including protein.
• Older adults and anyone who already has low muscle or bone strength may need a different plan than the trial averages suggest.

What people report

Fear of losing muscle is one of the most common worries people voice online about these medicines. The themes people commonly describe are starting a lifting routine, building meals around protein, and using protein shakes when appetite is low.

None of this was measured. People who are proud of their routine are more likely to post, and nobody checks how hard or how often they train. It is here because the topic is everywhere, and it is not evidence that any method works.

Quick answers

Do GLP-1 medicines make you lose muscle?

Some lean mass is lost along with fat, as with almost any large weight loss. In body scans, lean mass was about a quarter to a third of the weight lost. Scans cannot tell muscle from other lean tissue, and whether the loss weakens people in daily life is not settled.

How much muscle do you lose on Wegovy, Ozempic or Zepbound?

Trials report lean mass, not muscle. In a tirzepatide scan study, lean mass fell 10.9% over 72 weeks, against 2.6% on placebo. In a pooled analysis, lean mass was 35.2% of weight lost with semaglutide and 25.4% with tirzepatide.

Does eating more protein stop muscle loss on a GLP-1?

Not proven. Expert advice is to eat enough protein, often described as 1.2 to 1.6 g per kg of body weight a day. The Atlas found no finished trial testing a protein amount in people taking semaglutide or tirzepatide.

Does strength training help on a GLP-1 medicine?

It has the best support. In trials of weight-loss programs, those with resistance training lost a smaller share of the weight as lean mass. A Danish trial found exercise plus liraglutide improved body fat and fitness more than either alone. Trials built for people on semaglutide or tirzepatide are still under way.

Is there a drug that prevents muscle loss during weight loss?

Not yet. Bimagrumab and apitegromab slowed lean-mass loss in phase 2 trials, and neither is approved for that purpose.

Is lean mass loss the same as muscle loss?

No. Lean mass includes organs, skin and water as well as muscle, so a drop on a scan is only a rough guide to muscle.

Questions to ask

• Would a body scan help me, or can we track strength, waist size and how I feel instead?
• How much protein fits my size, my kidneys and my other conditions?
• Which strength exercises are safe for my joints and heart?
• Should I see a dietitian or a physical therapist?
• Does my age or my current muscle mass change the plan?
• Is bone health something to watch while I lose weight?

What is still unknown

• No finished randomized trial has tested a protein amount or a lifting program in people taking semaglutide or tirzepatide.
• Whether lean-mass loss on a scan means weaker muscles in daily life is not settled.
• Whether muscle-protecting drugs will reach approval, and what they cost in tolerability, bone and cholesterol, is not known.
• Supplements such as creatine, HMB and amino-acid products were not reviewed for this page.